55 results on '"Tewari, Krishnansu S."'
Search Results
2. Reply to P.-H. Luo et al.
3. Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial
4. Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
5. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
6. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
7. Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study.
8. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
9. Sentinel lymphatic mapping for gynecologic malignancies
10. Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
11. Risk factors for cervical cancer among distinct populations in low-resource countries: feasibility of cervical cancer screen-and-treat program on ukerewe island of lake victoria, Tanzania
12. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).
13. Minimally Invasive Surgery for Early-Stage Cervical Carcinoma: Interpreting the Laparoscopic Approach to Cervical Cancer Trial Results.
14. Survival With Cemiplimab in Recurrent Cervical Cancer
15. Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma.
16. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
17. Immune Checkpoint Blockade in PD-L1-Positive Platinum-Refractory Cervical Carcinoma.
18. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
19. Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study.
20. Immunotherapy plus chemoradiotherapy in cervical cancer management
21. Reply to Farolfi et al and Haines et al.
22. Bevacizumab in Cervical Cancer: 5 Years After.
23. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab
24. Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer
25. Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer
26. Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey
27. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
28. Changing paradigms in the systemic treatment of advanced cervical cancer.
29. Symptoms of Women With High-Risk Early-Stage Ovarian Cancer
30. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
31. Randomized Clinical Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
32. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma
33. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
34. Pathologic Findings at Risk-Reducing Salpingo-Oophorectomy: Primary Results From Gynecologic Oncology Group Trial GOG-0199.
35. Pemetrexed and Cisplatin for the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix: A Limited Access Phase II Trial of the Gynecologic Oncology Group.
36. Evidence-Based Therapy for Recurrent Cervical Cancer.
37. American Society of Clinical Oncology 2013.
38. Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer
39. American Society of Clinical Oncology 2012 Annual Meeting.
40. Advanced Cytoreductive Surgery Workshop Report.
41. Fertility preserving options in patients with gynecologic malignancies.
42. Pelvic Radiation Improves Local Control After Hysterectomy for Uterine Leiomyosarcoma.
43. Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
44. Cervical neoplasia in pregnancy. Part 1: screening and management of preinvasive disease.
45. Outside Slide Review in Gynecologic Oncology
46. Recent Achievements and Future Developments in Advanced and Recurrent Cervical Cancer: Trials of the Gynecologic Oncology Group
47. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
48. Primary invasive carcinoma of the vagina
49. The adventure of the three abnormal paps 21Note: Sherlock Holmes and Dr. Watson were created by Sir Arthur Conan Doyle (1859–1930).22The author wishes to acknowledge the dual literary geniuses of Britain’s Sir Arthur Conan Doyle and Alan Moore for inspiration.
50. Implementation of human papillomavirus video education for women participating in mass cervical cancer screening in Tanzania.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.